A cheap, decades-old chemotherapy drug extended life by more than a year when added to standard hormone therapy for men whose prostate cancer has widely spread, doctors reported. Christopher Sweeney, associate professor of medicine at the Dana-Farber Cancer Institute, led the study.
News & Research
